Get the Stockscreener App
4.40
1.90%
-0.085
After Hours:
4.32
-0.08
-1.82%
Lixte Biotechnology Holdings Inc stock is traded at $4.40, with a volume of 99,643.
It is down -1.90% in the last 24 hours and up +52.78% over the past month.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
See More
Previous Close:
$4.485
Open:
$4.55
24h Volume:
99,643
Relative Volume:
2.20
Market Cap:
$51.12M
Revenue:
-
Net Income/Loss:
$-6.01M
P/E Ratio:
-3.5711
EPS:
-1.2321
Net Cash Flow:
$-5.71M
1W Performance:
+25.71%
1M Performance:
+52.78%
6M Performance:
+2.56%
1Y Performance:
+272.88%
1-Day Range:
$3.96
$4.55
1-Week Range:
$3.29
$4.55
52-Week Range:
$0.64
$6.26
Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile
Name
Lixte Biotechnology Holdings Inc
Sector
Industry
Phone
310 203 2902
Address
433 PLAZA REAL, BOCA RATON
Compare LIXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIXT
Lixte Biotechnology Holdings Inc
|
4.40 | 52.11M | 0 | -6.01M | -5.71M | -1.2321 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Lixte Biotechnology Holdings, Inc. (LIXT) Latest Stock News & Headlines - Yahoo Finance
LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer Treatment - NewMediaWire
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Unlocking New Potential in Precision Cancer Treatment - TipRanks
LIXTE Biotechnology Advances Precision Oncology with Novel PP2A Inhibitor LB-100 - citybuzz -
LIXT Lixte posts Q4 2024 negative EPS of 27 cents and zero revenue, with shares unchanged today.EBITDA Margin - Cổng thông tin điện tử tỉnh Tây Ninh
LIXT Lixte Biotechnology Holdings Inc. shares gain 6.87 percent on positive investor reaction to Q4 2024 earnings release.Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - The Globe and Mail
Lixte (LIXT) Stock Volume Stability (Bearish Sentiment) 2026-04-20Crowd Entry Signals - Cổng thông tin điện tử tỉnh Lào Cai
LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape - NewMediaWire
Why Cardio Diagnostics Holdings (NASDAQ: CDIO) Is ‘One to Watch’ - Financial-News.co.uk
Lixte Biotechnology stock (US53833K1060): Is its PP2A cancer focus strong enough to unlock breakthro - AD HOC NEWS
Lixte Biotechnology Updates Executive Equity Compensation With RSUs - The Globe and Mail
Lixte Biotechnology Holdings, Inc. Files Form 8-K with SEC Detailing Restricted Share Unit Awards and Company Information (April 2026) - Minichart
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors - Investing.com India
LIXTE Biotechnology’s LB-100 Represents Novel Approach to Enhancing Cancer Therapies - citybuzz -
Lixte Biotechnology Holdings cancels options, grants RSUs to executives and directors By Investing.com - Investing.com South Africa
Lixte Biotechnology (LIXT) CEO cancels 350K options for shares - Stock Titan
Lixte (LIXT) CFO cancels 50K options, receives 50K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options and receives 25K RSUs - Stock Titan
LIXTE (LIXT) director cancels 25K options, receives 25K RSUs vesting immediately - Stock Titan
Lixte (LIXT) cancels insider stock options and grants fully vested RSUs - Stock Titan
Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built - The Globe and Mail
Lixte Biotechnology Holdings, Inc. (LIXTW) - Minichart
"NextEpochMarket company news.lhl"Results on X | Live Posts & Updates - x.com
LIXTE Biotechnology Reports Promising Interim Ovarian Cancer Trial Results at SGO Conference - citybuzz -
LIXTE Biotechnology (NASDAQ: LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - USA Today
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - NewMediaWire
Options Flow: What is the next catalyst for Lixte Biotechnology Holdings Inc Equity Warrant2026 Macro Impact & AI Forecast Swing Trade Picks - baoquankhu1.vn
Promising Clinical Trial Results for Lixte Biotechnology (LIXT) - GuruFocus
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference - GlobeNewswire
Geopolitics Watch: How volatile is Lixte Biotechnology Holdings Inc stock2026 Catalysts & Risk Controlled Daily Trade Plans - baoquankhu1.vn
LIXTE Biotechnology Expands Cancer Treatment Strategy with Acquisition and Clinical Advancements - citybuzz -
Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships - NewMediaWire
Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships - TipRanks
Aug Reactions: What is the cash position of Lixte Biotechnology Holdings Inc2026 Fundamental Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn
Lixte Biotech Advances Precision Oncology Strategy with LB-100 Therapy and Expanded Partnerships - citybuzz -
Valuation Update: Is Airship AI Holdings Inc part of any ETFPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Off: Is Lixte Biotechnology Holdings Inc attractive for institutional investors2026 Price Targets & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
ETF Watch: Is Lixte Biotechnology Holdings Inc affected by consumer sentiment2026 Technical Overview & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Is Lixte (LIXT) Stock Underperforming | Price at $3.08, Up 0.98%Target Price - Newser
LIXT Technical Analysis & Stock Price Forecast - Intellectia AI
Investor Mood: Is Lixte Biotechnology Holdings Inc stock forming a triangle pattern2026 Snapshot & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
LIXT PE Ratio & Valuation, Is LIXT Overvalued - Intellectia AI
Lixte Biotechnology Holdings, Inc. (LIXTW) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year - newmediawire.com
LIXTE Biotechnology Holdings (NASDAQ: LIXT) Files 2025 Form 10-K, Highlights Transformational Year - Financial-News.co.uk
LIXTE Biotechnology’s LB-100 May Transform Cancer Treatment—Yet Time Remains the Deciding Factor - bitget.com
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):